Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Subcutaneous Daratumumab (Dara-SC) in Multiple Myeloma
2018-004185-34Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoint: Rate of VGPR or better. Started Mar 2019; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-004185-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004185-34.